NCT01709656View on ClinicalTrials.gov

A Molecule Basic Study of Early Warning for New Pathogenic Risk of Ankylosing Spondylitis

NACompletedINTERVENTIONAL

Enrollment

120

Participants

Timeline

Start Date

March 31, 2012

Primary Completion Date

December 31, 2014

Study Completion Date

December 31, 2014

Conditions

Ankylosing Spondylitis

Interventions

BIOLOGICAL

MSC

"human mesenchymal stem cells,1\*10\^4-6 cells /Kg , IV (in the vein) on day 1 of each 14-60 day cycle,1-6 times treatment.~a total of 24 weeks for follow up."

DRUG

"celecoxib, Celebrex®"

"non-steroid anti-inflammatory drugs (NSAID):celecoxib, Celebrex® 0.2g Bid(twice a day),PO (Per Os);a total of 24 weeks for follow up"

Trial Locations (1)

Unknown

Department of Rheumatology, the Third Affiliated Hospital of Sun Yat-sen University, Guangzhou

All Listed Sponsors

lead

Sun Yat-sen University

OTHER

NCT01709656 - A Molecule Basic Study of Early Warning for New Pathogenic Risk of Ankylosing Spondylitis | Biotech Hunter | Biotech Hunter